Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis
Henry, Brandon Michael et. al.
MetadataShow full item record
In the fight against coronavirus disease 2019 (COVID-19), now a worldwide pandemic, urgent identification of clinical and laboratory predictors of progression towards severe and fatal forms is urgently needed. These predictors will enable risk stratification, guide interventional studies to target patients at enhanced risk of developing severe disease and optimize allocation of limited human and technical resources in the ongoing pandemic. Moreover, identification of laboratory parameters capable of discriminating between severe and non-severe cases, or those at high or low risk of mortality, will allow for improved clinical situational awareness. Though similarities are noted between COVID-19 and the severe acute respiratory syndrome (SARS), the World Health Organization (WHO) has observed differences in the clinical picture of the diseases caused by the two viruses. We have previously described the typical laboratory changes in both children and adults with COVID-19, observing some notable differences in laboratory parameters between COVID-19 and SARS viruses. In earlier reports, we have identified procalcitonin and platelet count as potential predictors of disease severity. However, with an increased volume of COVID-19 reports now published, it has enabled a more comprehensive analysis of laboratory data that is urgently needed by the medical and scientific communities. The aim of this study was to analyze laboratory abnormalities in patients with COVID-19, in order to define which parameters can discriminate between those who are at higher risk of developing severe vs. non-severe forms of disease, as well as those who are less likely to survive.